IBEX 35
11.032,30 -128,20 (-1,15%) Euro Stoxx 50
4.907,30 -40,43 (-0,82%) Dólar/Euro
1,0697 -0,0009 (-0,09%) Petróleo Brent
85,07 -0,64 (-0,75%) Oro
2.334,70 -34,30 (-1,45%) Bitcoin EUR
60.246,35 +152,79 (+0,25%)
Co-Diagnostics, Inc. (CODX)
Después del cierre:
Co-Diagnostics, Inc.
2401 South Foothill Drive
Suite D
Salt Lake City, UT 84109
United States
(801) 438-1036
https://www.codiagnostics.com
Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 155
Descripción
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Gobierno corporativo
El ISS Governance QualityScore de Co-Diagnostics, Inc., a día 1 de junio de 2024, es 9. Las puntuaciones base son Auditoría: 9; Tablero: 10; Derechos de los accionistas: 5; Compensación: 8.
